Zhizhu Kuanzhong Capsule for Patients With Functional Dyspepsia-Postprandial Distress Syndrome

Functional Dyspepsia Clinical Trial

— ZZKZ-FD  

Official title:

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Parallel Group Clinical Research of Zhizhu Kuanzhong Capsule in Treating Patients With Functional Dyspepsia-Postprandial Distress Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04380233
• Other study ID #: HKBU-FD
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2021
• Est. completion date: March 30, 2022

Study information

• Verified date: March 2022
• Source: Hong Kong Baptist University
• Contact: Linda Zhong, MD., Ph.D
• Phone: 852-34116523
• Email: ldzhong0305[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A 13 weeks randomized, double-blind and placebo parallel-controlled trial will be conducted to evaluate the clinical efficacy and safety of Zhizhu Kuanzhong Capsule in the treatment of functional dyspepsia-postprandial distress syndrome.

Description:

This is a multi-center, randomized, double-blind, placebo parallel-controlled International clinical trial of Zhizhu Kuanzhong Capsule in treating patients with Functional Dyspepsia-Postprandial Distress Syndrome (FD-PDS). In this study, Hong Kong Baptist University will collaborate with Xiyuan Hospital of China Academy of Chinese Medical Sciences, and will be recruiting 60 FD-PDS patients as study subjects in Hong Kong, out of the total sample size of 480 patients. The study includes a 1 week run-in period, 8 weeks double-blind treatment period and a 4 weeks of follow up period for each eligible subject. Eligible subjects will be randomly assigned to either the trial drug or the placebo. 6 follow-up visits and 1 telephone follow-up will be scheduled for each subject on the -7 days (visit 1), enrollment on day 0 (visit 2), 14th day (visit 3), 28th day (visit 4), 42nd day (visit 5, telephone follow-up), the 56th day (visit 6) and the 84th day (visit 7) respectively. Urine, stool and blood samples will be collected from each subject on visit 2 and visit 6 for blood, urine, stool, liver and kidney function tests.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 30, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Meeting the Rome IV diagnostic criteria for functional dyspepsia-postprandial distress syndrome;

2. At least 3 days during the one-week run-in period with VAS score = 4 for major symptoms (at least one of postprandial fullness discomfort and early satiety) .

3. Be able to discontinue prohibited medications that may affect the evaluation of the effectiveness.

4. Written informed consent.

Exclusion Criteria:

1. Gastroscopic findings of gastric cancer, peptic ulcer, erosive gastritis (grade 2 or higher), moderate to severe atrophic gastritis, dysplasia, or other organ gastrointestinal disease.

2. History of abdominal surgery (except for appendectomy and cesarean section);

3. Immune system defects, or those who have been administered immunosuppressive agents or glucocorticoids within the past 3 months.

4. With combined severe cardiac and pulmonary insufficiency, insufficiency of liver (ALT/AST > 1.5 times the upper limit of the normal value), kidney insufficiency (BUN/SCr > the upper limit of the normal value), abnormal of endocrine system, abnormal hematopoietic system, and iron deficiency anemia as indicated on hematological examination.

5. With severe anxiety and depression.

6. With psychosis and mental retardation, language disorder precluding the ability of filling scales or recording symptoms.

7. Pregnancy or lactating; or patients of childbearing potential without effective contraception.

8. known to be allergic to the ingredients of this drug.

9. suspected or confirmed history of alcohol or drug abuse.

10. have participated in a clinical trial in the past 3 months.

11. deemed by the investigator as being not suitable for participation in the clinical trial.

Related Conditions & MeSH terms

• Dyspepsia
• Functional Dyspepsia

Intervention

Drug:
• Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome
The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
• Placebo capsules
The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.

Locations

Country	Name	City	State
Hong Kong	Linda Zhong	Kowloon Tong	Kowloon

Sponsors (2)

Lead Sponsor	Collaborator
Hong Kong Baptist University	Xiyuan Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Analogue Score (VAS)	Subjects with the functional dyspepsia-postprandial distress syndrome are self-rated on the Visual Analogue Score (VAS) for the degree of discomfort with both symptoms of postprandial fullness and early fullness, with subjects indicating the degree of discomfort on a 10 cm ruler marked 0- "Asymptomatic or No Discomfort "and 10- "Extreme Severe or Extreme Discomfort "at its head and tail, respectively. The record is made on the diary card once a day and 7 days a week.; The integral average for the sum of VAS for both two symptoms over the past week is evaluated based on the diary card content, and a 50% decrease from baseline in the integral average at 8 weeks is recorded as a response. The proportion of the response at 8 weeks after randomization is considered primary efficacy endpoint.	For 8 weeks
Secondary	Evaluation of individual symptoms of Functional Dyspepsia	The subjects were evaluated using a symptom diary for Functional Dyspepsia based on the Visual Analogue Score (VAS) for gastrointestinal symptoms, including postprandial fullness discomfort, early satiety, abdominal distension, abdominal pain, epigastric burning sensation, nausea, excessive eructation, heartburn, vomiting, regurgitation, dysphagia, rass, abdominal enlargement, and defecation smoothness. Subjects indicated their discomfort on a 10 cm ruler marked 0-"asymptomatic or no discomfort" and 10-"very painful or extremely uncomfortable" on the head and tail respectively. The rating is made once a day and 7 days a week. The investigator used the average of the weekly VAS scores recorded in the subject's diary card as the symptom intensity score for this week, with one VAS score per week. The change of VAS score of each symptom at 8 weeks after randomization relative to the base	For 8 weeks
Secondary	Overall Treatment Evaluation scale (OTE)	The overall treatment efficacy is evaluated using a 7point Likert Overall Evaluation Scale (OTE). The clinical investigators asked the subjects the following questions at the visit: "In the last week, how much have your dyspeptic symptoms been alleviated as compared to pre-treatment?" There are 7 options: ? the symptoms improved significantly, ? the symptoms improved, ? the symptoms improved slightly, ? the symptoms did not change, ? the symptoms aggravated slightly, ? the symptoms aggravated, ? the symptoms aggravated significantly. At the last visit time point of the treatment cycle, patients who selected ? -? were defined as treatment responders, and those who selected ? -? were defined as non-responders. The response rates at 8 weeks between the groups were compared for differences.	For 8 weeks
Secondary	Hospital Anxiety and Depression Scale (HAD) score	HAD Rating Scale scores are recorded at baseline, week 4 and week 8 during the double-blind treatment respectively. 14 questions are asked about the subject's emotional changes that best match his/her mood since the last month.	At baseline, week 4 and week 8
Secondary	Short Form-Nepean Dyspepsia Index (SFNDI)	Short Form-Nepean Dyspepsia Index (SFNDI) is recorded at baseline, week 4 and week 8 during the double-blind treatment respectively. 10 Questions are asked about how the subject's stomach pain, discomfort, or other epigastric symptoms over the last 14 days have affected his/her life.	At baseline, week 4 and week 8